How Durable Is the Hepatitis B Vaccine?

About 85% of a cohort of Alaskans who received the hepatitis B vaccine at age 6 months or older showed evidence of protection after 35 years, although some may require a booster dose, according to a study presented at the 2017 Liver Meeting. “No chronic hepatitis B infections were identified in the cohort,” according to lead study author Michael Bruce, MD, MPH, an epidemiology team leader in the CDC’s Arctic Investigation Program Division of Preparedness

ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study

EDISON, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today new findings confirming that CRV431, a cyclophilin inhibitor, reduces the number and size of liver tumors in a hepatocellular carcinoma (HCC) mouse model. Data from the study indicate that CRV431 reduced th

The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

BRIEF: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B

IN BRIEF: RECOMMENDATION The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF). Read more: https://www.cadth.ca/tenofovir-alafenamide  

This Common Viral Disease Has Plagued Humanity Thousands of Years Longer Than We Thought

Evidence of Hepatitis B has been found in human DNA dating back to the Bronze Age, around 4,500 years ago. We now have proof that it infected humans broadly across Eurasia for millennia, pushing back the earliest evidence we have by thousands of years. Previously, the earliest evidence of Hepatitis B was just 450 years old - and its discovery in a mummified medieval Italian child was only announced earlier this year. A team led by geneticist Eske Wille

The Week in Review: April 20 – April 27, 2018

Friday, April 27, 2018 News Recap: Warnings: Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...

NCCN: Screen for Liver Cancer in Patients at Risk

In the last 20 years in the United States, the incidence of hepatocellular carcinoma (HCC) has tripled from about 2 to 7 per 100,000 adults. In addition to the rising incidence, the cancer is also one of the most deadly, with a 5-year survival rate of only 18%. These comments were made here by Anne Covey, MD, a radiologist from the Memorial Sloan Kettering Cancer Center, New York City, at the National Comprehensive Cancer Network (NCCN) 23rd Annual Confer

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

About 1 in 4 people with chronic hepatitis B (HBV) infection who reside in North America have metabolic syndrome, which was also independently associated with higher alanine aminotransferase (ALT) levels over time, according to a new study published in Diabetes Care. Metabolic syndrome is a risk factor for chronic liver disease progression, and aside from being directly associated with nonalcoholic fatty liver disease, metabolic syndrome could influence o

The Week in Review: March 23 – April 6, 2018

Friday, April 6, 2018 News Recap: HCV – Liver Cancer (HCC): Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. Testing for he...

Obesity Linked to Increased Risk of Liver Cancer in Hepatitis B Patients

MedicalResearch.com Interview with: Sang Min Park MD, MPH, PhD:  Chief, Department of Family Medicine, Seoul National University College of Medicine; Director, Health Promotion Center, Seoul National University Hospital; Professor, Department of Biomedical Science & Family Medicine Seoul National University College of Medicine, Seoul, Korea What is the background for this study? What are the main findings? Response: Chronic hepatitis B patients hav